Neurocrine Biosciences (NBIX) Cash & Current Investments (2016 - 2021)
Historic Cash & Current Investments for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $765.9 million.
- Neurocrine Biosciences' Cash & Current Investments fell 1892.66% to $765.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $765.9 million, marking a year-over-year decrease of 1892.66%. This contributed to the annual value of $804.2 million for FY2020, which is 1994.03% up from last year.
- Per Neurocrine Biosciences' latest filing, its Cash & Current Investments stood at $765.9 million for Q3 2021, which was down 1892.66% from $884.9 million recorded in Q2 2021.
- Over the past 5 years, Neurocrine Biosciences' Cash & Current Investments peaked at $948.3 million during Q2 2020, and registered a low of $235.6 million during Q1 2017.
- In the last 5 years, Neurocrine Biosciences' Cash & Current Investments had a median value of $650.9 million in 2018 and averaged $659.0 million.
- Its Cash & Current Investments has fluctuated over the past 5 years, first crashed by 3825.29% in 2017, then skyrocketed by 9546.61% in 2018.
- Quarter analysis of 5 years shows Neurocrine Biosciences' Cash & Current Investments stood at $515.9 million in 2017, then rose by 26.16% to $650.9 million in 2018, then grew by 3.01% to $670.5 million in 2019, then rose by 19.94% to $804.2 million in 2020, then dropped by 4.76% to $765.9 million in 2021.
- Its last three reported values are $765.9 million in Q3 2021, $884.9 million for Q2 2021, and $873.7 million during Q1 2021.